LU91281I2 - Preotact-hormone parathyroïde - Google Patents

Preotact-hormone parathyroïde

Info

Publication number
LU91281I2
LU91281I2 LU91281C LU91281C LU91281I2 LU 91281 I2 LU91281 I2 LU 91281I2 LU 91281 C LU91281 C LU 91281C LU 91281 C LU91281 C LU 91281C LU 91281 I2 LU91281 I2 LU 91281I2
Authority
LU
Luxembourg
Prior art keywords
parathyroid hormone
preotact
pharmaceutical formulations
osteoporosis
useful
Prior art date
Application number
LU91281C
Other languages
English (en)
French (fr)
Original Assignee
Nps Allelix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Allelix Corp filed Critical Nps Allelix Corp
Publication of LU91281I2 publication Critical patent/LU91281I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
LU91281C 1998-04-28 2006-10-19 Preotact-hormone parathyroïde LU91281I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801495A SE9801495D0 (sv) 1998-04-28 1998-04-28 Protein formulationa

Publications (1)

Publication Number Publication Date
LU91281I2 true LU91281I2 (fr) 2006-12-19

Family

ID=20411122

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91281C LU91281I2 (fr) 1998-04-28 2006-10-19 Preotact-hormone parathyroïde

Country Status (24)

Country Link
US (1) US20050209144A1 (OSRAM)
EP (1) EP1079803B1 (OSRAM)
JP (2) JP4733267B2 (OSRAM)
KR (1) KR100579872B1 (OSRAM)
CN (1) CN1172658C (OSRAM)
AT (1) ATE273693T1 (OSRAM)
AU (2) AU766514B2 (OSRAM)
BR (1) BR9909958A (OSRAM)
CA (1) CA2329800C (OSRAM)
CY (1) CY2006006I2 (OSRAM)
DE (3) DE122006000057I2 (OSRAM)
DK (1) DK1079803T3 (OSRAM)
ES (1) ES2224637T3 (OSRAM)
FR (1) FR06C0032I2 (OSRAM)
HK (1) HK1041218B (OSRAM)
IL (1) IL139320A (OSRAM)
LU (1) LU91281I2 (OSRAM)
NL (1) NL300243I2 (OSRAM)
NZ (1) NZ508269A (OSRAM)
PT (1) PT1079803E (OSRAM)
SE (1) SE9801495D0 (OSRAM)
SI (1) SI1079803T1 (OSRAM)
WO (1) WO1999055353A2 (OSRAM)
ZA (1) ZA200006040B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Pthの安定化水溶液注射剤
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
KR101891673B1 (ko) * 2011-06-07 2018-08-27 아사히 가세이 파마 가부시키가이샤 고순도 pth 함유 동결 건조 제제 및 그의 제조 방법
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN108333360A (zh) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 胃泌素释放肽前体稀释液及其应用和试剂盒
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
JP2662842B2 (ja) * 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
AU3095092A (en) * 1991-12-09 1993-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
ES2179831T3 (es) * 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH09157294A (ja) * 1995-06-15 1997-06-17 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
JP4053107B2 (ja) * 1996-02-01 2008-02-27 中外製薬株式会社 血小板減少症の予防剤および治療剤
US5964807A (en) * 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa

Also Published As

Publication number Publication date
SE9801495D0 (sv) 1998-04-28
JP5753692B2 (ja) 2015-07-22
CN1319003A (zh) 2001-10-24
CY2006006I1 (el) 2009-11-04
JP2011105739A (ja) 2011-06-02
AU766514B2 (en) 2003-10-16
ZA200006040B (en) 2002-01-28
KR100579872B1 (ko) 2006-05-12
EP1079803B1 (en) 2004-08-18
WO1999055353A3 (en) 2000-01-13
DE69919533T2 (de) 2005-09-08
NZ508269A (en) 2003-12-19
FR06C0032I2 (fr) 2007-04-27
IL139320A0 (en) 2001-11-25
BR9909958A (pt) 2000-12-26
CA2329800A1 (en) 1999-11-04
AU3591699A (en) 1999-11-16
ATE273693T1 (de) 2004-09-15
EP1079803A2 (en) 2001-03-07
DK1079803T3 (da) 2004-11-22
DE122006000057I2 (de) 2009-11-05
IL139320A (en) 2007-06-17
CY2006006I2 (el) 2009-11-04
NL300243I1 (nl) 2006-12-01
NL300243I2 (nl) 2007-02-01
DE69919533D1 (de) 2004-09-23
WO1999055353A2 (en) 1999-11-04
US20050209144A1 (en) 2005-09-22
AU2004200156B2 (en) 2005-12-15
KR20010052276A (ko) 2001-06-25
CA2329800C (en) 2004-06-15
HK1041218B (zh) 2005-03-18
DE122006000057I1 (de) 2007-01-04
CN1172658C (zh) 2004-10-27
ES2224637T3 (es) 2005-03-01
HK1041218A1 (en) 2002-07-05
AU2004200156A1 (en) 2004-02-12
PT1079803E (pt) 2004-11-30
JP2002512973A (ja) 2002-05-08
SI1079803T1 (en) 2005-02-28
JP4733267B2 (ja) 2011-07-27
FR06C0032I1 (OSRAM) 2006-11-24

Similar Documents

Publication Publication Date Title
LU91281I2 (fr) Preotact-hormone parathyroïde
YU83502A (sh) Nova farmaceutska smeša
BR0008059A (pt) Composições de valdecoxib
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
PT994710E (pt) Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
YU7797A (sh) Kombinovana terapija za osteoporozu
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
DK1420827T3 (da) 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
EP1469717A4 (en) TRIPLE TRANSGENIC MOUSE MODEL FOR MORBUS ALZHEIMER
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
UY27373A1 (es) Formulaciones de interferón beta-humano
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
GB9823515D0 (en) Agent for the treatment of osteoporosis
IT1307866B1 (it) Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих